The proteasome: a suitable antineoplastic target (original) (raw)

• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Ciechanover, A. The ubiquitin–proteasome proteolytic pathway. Cell 79, 13–21 (1994).
  Article CAS PubMed Google Scholar
• Hough, R., Pratt, G. & Rechsteiner, M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J. Biol. Chem. 262, 8303–8313 (1987).
  Article CAS PubMed Google Scholar
• Waxman, L., Fagan, J. M. & Goldberg, A. L. Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates. J. Biol. Chem. 262, 2451–2457 (1987).
  Article CAS PubMed Google Scholar
• Bortezomib (Velcade) for multiple myeloma. Med. Lett. Drugs Ther. 45, 57–58 (2003).
• Brooks, P. et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem. J. 346, 155–161 (2000). This paper demonstrates the complexity of proteasomal populations and localizations in mammalian cells.
  Article CAS PubMed PubMed Central Google Scholar
• Peters, J. M., Cejka, Z., Harris, J. R., Kleinschmidt, J. A. & Baumeister, W. Structural features of the 26 S proteasome complex. J. Mol. Biol. 234, 932–937 (1993).
  Article CAS PubMed Google Scholar
• Elliott, P. J. & Ross, J. S. The proteasome: a new target for novel drug therapies. Am. J. Clin. Pathol. 116, 637–646 (2001).
  Article CAS PubMed Google Scholar
• Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367–380 (1998).
  Article CAS PubMed Google Scholar
• Ciechanover, A. The ubiquitin–proteasome pathway: on protein death and cell life. EMBO J. 17, 7151–7160 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• DeMartino, G. N. & Slaughter, C. A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274, 22123–22126 (1999).
  Article CAS PubMed Google Scholar
• Kisselev, A. F., Akopian, T. N., Castillo, V. & Goldberg, A. L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell 4, 395–402 (1999).
  Article CAS PubMed Google Scholar
• Goldberg, A. L., Cascio, P., Saric, T. & Rock, K. L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39, 147–164 (2002).
  Article CAS PubMed Google Scholar
• Kisselev, A. F. et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem. 278, 35869–35877 (2003).
  Article CAS PubMed Google Scholar
• Glickman, M. H. et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 94, 615–623 (1998).
  Article CAS PubMed Google Scholar
• Benaroudj, N., Zwickl, P., Seemuller, E., Baumeister, W. & Goldberg, A. L. ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol. Cell 11, 69–78 (2003).
  Article CAS PubMed Google Scholar
• Kalejta, R. F. & Shenk, T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl Acad. Sci. USA 100, 3263–3268 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Benaroudj, N., Tarcsa, E., Cascio, P. & Goldberg, A. L. The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes. Biochimie 83, 311–318 (2001).
  Article CAS PubMed Google Scholar
• Ahn, K. et al. In vivo characterization of the proteasome regulator PA28. J. Biol. Chem. 271, 18237–18242 (1996).
  Article CAS PubMed Google Scholar
• Ma, C. P., Slaughter, C. A. & DeMartino, G. N. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem. 267, 10515–10523 (1992).
  Article CAS PubMed Google Scholar
• Mott, J. D. et al. PA28, an activator of the 20 S proteasome, is composed of two nonidentical but homologous subunits. J. Biol. Chem. 269, 31466–31471 (1994).
  Article CAS PubMed Google Scholar
• Nikaido, T. et al. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 79, 209–214 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Realini, C. et al. Characterization of recombinant REGα, REGβ, and REGγ proteasome activators. J. Biol. Chem. 272, 25483–25492 (1997).
  Article CAS PubMed Google Scholar
• Rechsteiner, M., Realini, C. & Ustrell, V. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem. J. 345, 1–15 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Groettrup, M. et al. A role for the proteasome regulator PA28α in antigen presentation. Nature 381, 166–168 (1996).
  Article CAS PubMed Google Scholar
• Murata, S. et al. Immunoproteasome assembly and antigen presentation in mice lacking both PA28α and PA28β. EMBO J. 20, 5898–5907 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Gaczynska, M., Rock, K. L. & Goldberg, A. L. γ-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264–267 (1993).
  Article CAS PubMed Google Scholar
• Bose, S., Brooks, P., Mason, G. G. & Rivett, A. J. γ-interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation. Biochem. J. 353, 291–297 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hill, C. P., Masters, E. I. & Whitby, F. G. The 11S regulators of 20S proteasome activity. Curr. Top. Microbiol. Immunol. 268, 73–89 (2002).
  CAS PubMed Google Scholar
• Whitby, F. G. et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408, 115–120 (2000).
  Article CAS PubMed Google Scholar
• Realini, C., Rogers, S. W. & Rechsteiner, M. KEKE motifs. Proposed roles in protein-protein association and presentation of peptides by MHC class I receptors. FEBS Lett. 348, 109–113 (1994).
  Article CAS PubMed Google Scholar
• Palmer, A. et al. Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol. Biochem. J. 316, 401–407 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Amsterdam, A., Pitzer, F. & Baumeister, W. Changes in intracellular localization of proteasomes in immortalized ovarian granulosa cells during mitosis associated with a role in cell cycle control. Proc. Natl Acad. Sci. USA 90, 99–103 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Palmer, A., Mason, G. G., Paramio, J. M., Knecht, E. & Rivett, A. J. Changes in proteasome localization during the cell cycle. Eur. J. Cell Biol. 64, 163–175 (1994).
  CAS PubMed Google Scholar
• Lafarga, M., Fernandez, R., Mayo, I., Berciano, M. T. & Castano, J. G. Proteasome dynamics during cell cycle in rat Schwann cells. Glia 38, 313–328 (2002).
  Article PubMed Google Scholar
• Reits, E. A., Benham, A. M., Plougastel, B., Neefjes, J. & Trowsdale, J. Dynamics of proteasome distribution in living cells. EMBO J. 16, 6087–6094 (1997). This paper demonstrates the free and rapid diffusion of the vast majority (> 90%) of the proteasome within, but not between, the cytoplasmic and nuclear compartments of the cell, and how the cytoplasmically generated proteasome enters the nucleus.
  Article CAS PubMed PubMed Central Google Scholar
• Wojcik, C. & DeMartino, G. N. Intracellular localization of proteasomes. Int. J. Biochem. Cell Biol. 35, 579–589 (2003).
  Article CAS PubMed Google Scholar
• Gordon, C. The intracellular localization of the proteasome. Curr. Top. Microbiol. Immunol. 268, 175–184 (2002).
  CAS PubMed Google Scholar
• Pickart, C. M. Ubiquitin enters the new millennium. Mol. Cell 8, 499–504 (2001).
  Article CAS PubMed Google Scholar
• Hicke, L. A new ticket for entry into budding vesicles-ubiquitin. Cell 106, 527–530 (2001).
  Article CAS PubMed Google Scholar
• Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895–899 (2003).
  Article CAS PubMed Google Scholar
• Yang, Y. & Yu, X. Regulation of apoptosis: the ubiquitous way. FASEB J. 17, 790–799 (2003).
  Article CAS PubMed Google Scholar
• King, R. W., Deshaies, R. J., Peters, J. M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652–1659 (1996).
  Article CAS PubMed Google Scholar
• Murray, A. W. Recycling the cell cycle: cyclins revisited. Cell 116, 221–234 (2004).
  Article CAS PubMed Google Scholar
• Glotzer, M., Murray, A. W. & Kirschner, M. W. Cyclin is degraded by the ubiquitin pathway. Nature 349, 132–138 (1991).
  Article CAS PubMed Google Scholar
• Diehl, J. A., Zindy, F. & Sherr, C. J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11, 957–972 (1997).
  Article CAS PubMed Google Scholar
• Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M. & Roberts, J. M. Turnover of cyclin E by the ubiquitin–proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10, 1979–1990 (1996).
  Article CAS PubMed Google Scholar
• Pagano, M. et al. Role of the ubiquitin–proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682–685 (1995).
  Article CAS PubMed Google Scholar
• Shirane, M. et al. Down-regulation of p27Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 274, 13886–13893 (1999).
  Article CAS PubMed Google Scholar
• Tam, S. W., Theodoras, A. M. & Pagano, M. Kip1 degradation via the ubiquitin–proteasome pathway. Leukemia 11(Suppl 3), 363–366 (1997).
  PubMed Google Scholar
• Mailand, N. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425–1429 (2000).
  Article CAS PubMed Google Scholar
• Bernardi, R., Liebermann, D. A. & Hoffman, B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 19, 2447–2454 (2000).
  Article CAS PubMed Google Scholar
• Baldin, V., Cans, C., Knibiehler, M. & Ducommun, B. Phosphorylation of human CDC25B phosphatase by CDK1–cyclin A triggers its proteasome-dependent degradation. J. Biol. Chem. 272, 32731–32734 (1997).
  Article CAS PubMed Google Scholar
• Chen, F. et al. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 99, 1990–1995 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Chène, P. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 3, 102–109 (2003).
  Article CAS Google Scholar
• Soussi, T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. NY Acad. Sci. 910, 121–137 (2000).
  Article CAS PubMed Google Scholar
• Momand, J., Wu, H. H. & Dasgupta, G. MDM2—master regulator of the p53 tumor suppressor protein. Gene 242, 15–29 (2000).
  Article CAS PubMed Google Scholar
• Sherr, C. J. & Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94–99 (2000).
  Article CAS PubMed Google Scholar
• Maki, C. G., Huibregtse, J. M. & Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56, 2649–2654 (1996).
  CAS PubMed Google Scholar
• Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299–303 (1997).
  Article CAS PubMed Google Scholar
• Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296–299 (1997).
  Article CAS PubMed Google Scholar
• Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25–27 (1997).
  Article CAS PubMed Google Scholar
• Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945–8951 (2000).
  Article CAS PubMed Google Scholar
• Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301–310 (2002).
  Article CAS Google Scholar
• Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).
  Article CAS PubMed Google Scholar
• Li, C. C., Dai, R. M. & Longo, D. L. Inactivation of NF-κB inhibitor IκBα: ubiquitin-dependent proteolysis and its degradation product. Biochem. Biophys. Res. Commun. 215, 292–301 (1995).
  Article CAS PubMed Google Scholar
• Adams, J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8, S49–S54 (2002).
  Article CAS PubMed Google Scholar
• Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. & Baldwin, A. S. Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680–1683 (1998). An early study demonstrating that proteasome inhibition induces apoptosis in proliferating (but not quiescent and differentiated) leukaemic cells in a manner that is associated with the activation of CPP32 and increased KIP1 levels.
  Article CAS PubMed Google Scholar
• Varfolomeev, E. E. et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 9, 267–276 (1998).
  Article CAS PubMed Google Scholar
• Drexler, H. C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl Acad. Sci. USA 94, 855–860 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Masdehors, P. et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 105, 752–757 (1999).
  Article CAS PubMed Google Scholar
• Drexler, H. C., Risau, W. & Konerding, M. A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 14, 65–77 (2000).
  Article CAS PubMed Google Scholar
• Kudo, Y. et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 6, 916–923 (2000).
  CAS PubMed Google Scholar
• Bogner, C. et al. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and-independent pathways. Exp. Hematol. 31, 218–225 (2003).
  Article CAS PubMed Google Scholar
• Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071–3076 (2001).
  CAS PubMed Google Scholar
• Guzman, M. L. et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl Acad. Sci. USA 99, 16220–16225 (2002). This study shows the ability of proteasome inhibition to combine well with anthracycline therapy to target leukaemic cells in vitro and in vivo , through NF-κB- and p53-related mechanisms.
  Article CAS PubMed PubMed Central Google Scholar
• Stirewalt, D. L. et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97, 3589–3595 (2001).
  Article CAS PubMed Google Scholar
• Schenkein, D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma 3, 49–55 (2002).
  Article CAS PubMed Google Scholar
• Masdehors, P. et al. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 96, 269–274 (2000).
  Article CAS PubMed Google Scholar
• Kordes, U., Krappmann, D., Heissmeyer, V., Ludwig, W. D. & Scheidereit, C. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14, 399–402 (2000).
  Article CAS PubMed Google Scholar
• Feinman, R. et al. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93, 3044–3052 (1999).
  Article CAS PubMed Google Scholar
• Ni, H. et al. Analysis of expression of nuclear factor κB (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br. J. Haematol. 115, 279–286 (2001).
  Article CAS PubMed Google Scholar
• Jeremias, I. et al. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 91, 4624–4631 (1998). This paper demonstrates that inhibition of NF-κB activity, either through proteasome inhibition or by mutant IκBα, increases the sensitivity of cells to apoptosis, including cells resistant to apoptosis, following treatment with various agents.
  Article CAS PubMed Google Scholar
• Bentires-Alj, M. et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22, 90–97 (2003).
  Article CAS PubMed Google Scholar
• Adams, J., Palombella, V. J. & Elliott, P. J. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs 18, 109–121 (2000).
  Article CAS PubMed Google Scholar
• Almond, J. B. & Cohen, G. M. The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433–443 (2002).
  Article CAS PubMed Google Scholar
• Figueiredo-Pereira, M. E., Chen, W. E., Li, J. & Johdo, O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J. Biol. Chem. 271, 16455–16459 (1996).
  Article CAS PubMed Google Scholar
• Lum, R. T. et al. A new structural class of proteasome inhibitors that prevent NF-κB activation. Biochem. Pharmacol. 55, 1391–1397 (1998).
  Article CAS PubMed Google Scholar
• Lum, R. T. et al. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides. Bioorg. Med. Chem. Lett. 8, 209–214 (1998).
  Article CAS PubMed Google Scholar
• Wilk, S., Pereira, M. & Yu, B. Probing the specificity of the bovine pituitary multicatalytic proteinase complex by inhibitors, activators, and by chemical modification. Biomed. Biochim. Acta 50, 471–478 (1991).
  CAS PubMed Google Scholar
• Orlowski, M., Cardozo, C. & Michaud, C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 32, 1563–1572 (1993).
  Article CAS PubMed Google Scholar
• Meng, L., Kwok, B. H., Sin, N. & Crews, C. M. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 59, 2798–2801 (1999).
  CAS PubMed Google Scholar
• Kim, K. B., Myung, J., Sin, N. & Crews, C. M. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg. Med. Chem. Lett. 9, 3335–3340 (1999).
  Article CAS PubMed Google Scholar
• Bogyo, M. et al. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl Acad. Sci. USA 94, 6629–6634 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Elliott, P. J., Zollner, T. M. & Bochncke, W. -H. Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med. 81, 235–245 (2003).
  Article CAS PubMed Google Scholar
• An, B., Goldfarb, R. H., Siman, R. & Dou, Q. P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5, 1062–1075 (1998).
  Article CAS PubMed Google Scholar
• Adams, J. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333–338 (1998).
  Article CAS PubMed Google Scholar
• Shah, I. M., Lees, K. R., Pien, C. P. & Elliott, P. J. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 54, 269–276 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Andre, P. et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl Acad. Sci. USA 95, 13120–13124 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615–2622 (1999). A key paper describing the selection, characteristics, and early in vitro and in vivo studies of PS-341, later named bortezomib.
  CAS PubMed Google Scholar
• Dietrich, C., Bartsch, T., Schanz, F., Oesch, F. & Wieser, R. J. p53-dependent cell cycle arrest induced by _N_-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl Acad. Sci. USA 93, 10815–10819 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Lopes, U. G., Erhardt, P., Yao, R. & Cooper, G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272, 12893–12896 (1997).
  Article CAS PubMed Google Scholar
• Ling, Y. H. et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther. 1, 841–849 (2002).
  CAS PubMed Google Scholar
• Dou, Q. P., McGuire, T. F., Peng, Y. & An, B. Proteasome inhibition leads to significant reduction of Bcr–Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J. Pharmacol. Exp. Ther. 289, 781–790 (1999).
  CAS PubMed Google Scholar
• Yu, C. L. & Burakoff, S. J. Involvement of proteasomes in regulating Jak–STAT pathways upon interleukin-2 stimulation. J. Biol. Chem. 272, 14017–14020 (1997).
  Article CAS PubMed Google Scholar
• Callus, B. A. & Mathey-Prevot, B. Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors. Blood 91, 3182–3192 (1998).
  Article CAS PubMed Google Scholar
• Pasquini, L. A., Paez, P. M., Moreno, M. A., Pasquini, J. M. & Soto, E. F. Inhibition of the proteasome by lactacystin enhances oligodendroglial cell differentiation. J. Neurosci. 23, 4635–4644 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Shah, S. A. et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 82, 110–122 (2001).
  Article CAS PubMed Google Scholar
• Russo, S. M. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 50, 183–193 (2001). This paper demonstrates the ability of bortezomib to enhance the sensitivity of neoplastic cells to radiation therapy in vitro and in vivo in a manner that is associated with the inhibition of radiation-induced NF-κB activation.
  Article CAS PubMed Google Scholar
• Cusack, J. C. Jr. et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61, 3535–3540 (2001). A demonstration of the ability of bortezomib to act in combination with conventional chemotherapy in solid tumour cells in vitro and in vivo . This paper also demonstrates the ability of bortezomib to inhibit the NF-κB activation induced by SN-38.
  CAS PubMed Google Scholar
• Ma, M. H. et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9, 1136–1144 (2003).
  CAS PubMed Google Scholar
• Lenz, H. J. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat. Rev. 29(Suppl 1), 41–48 (2003).
  Article CAS PubMed Google Scholar
• Chauhan, D. et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 63, 6174–6177 (2003).
  CAS PubMed Google Scholar
• Chandra, J. et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92, 4220–4229 (1998).
  Article CAS PubMed Google Scholar
• Gatto, S. et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88, 853–863 (2003).
  CAS PubMed Google Scholar
• Hideshima, T. et al. NF-kB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639–16647 (2002).
  Article CAS PubMed Google Scholar
• Mitsiades, N. et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99, 14374–14379 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Hideshima, T. et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101, 1530–1534 (2003).
  Article CAS PubMed Google Scholar
• LeBlanc, R. et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996–5000 (2002).
  CAS PubMed Google Scholar
• Sunwoo, J. B. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7, 1419–1428 (2001).
  CAS PubMed Google Scholar
• Teicher, B. A., Ara, G., Herbst, R., Palombella, V. J. & Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638–2645 (1999).
  CAS PubMed Google Scholar
• Wang, C. Y., Cusack, J. C. J., Liu, R. & Baldwin, A. S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nature Med. 5, 412–417 (1999).
  Article CAS PubMed Google Scholar
• Mitsiades, N. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377–2380 (2003). This paper demonstrates the synergistic activity of bortezomib used in combination with DNA-damaging agents in multiple myeloma cells, as well as the ability of bortezomib to remove cell-adhesion-mediated drug resistance. Bortezomib is also shown to downregulate multiple DNA-repair proteins.
  Article CAS PubMed Google Scholar
• Bold, R. J., Virudachalam, S. & McConkey, D. J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100, 11–17 (2001).
  Article CAS PubMed Google Scholar
• Aghajanian, C. et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2505–2511 (2002).
  CAS PubMed Google Scholar
• Orlowski, R. Z. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420–4427 (2002). One of two key Phase I clinical trials of bortezomib. This was a dose-ranging study in patients with advanced haematological malignancies, including multiple myeloma. The study demonstrated patient responses and acceptable toxicities and, in conjunction with reference 125, helped define the dose for the Phase II trials.
  Article CAS PubMed Google Scholar
• Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617 (2003). The key Phase II trial that led to the approval of the first proteasome inhibitor for the treatment of patients with multiple myeloma.
  Article CAS PubMed Google Scholar
• Read, M. A. et al. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2, 493–506 (1995).
  Article CAS PubMed Google Scholar
• Nefedova, Y., Landowski, T. H. & Dalton, W. S. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17, 1175–1182 (2003).
  Article CAS PubMed Google Scholar
• Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658–1667 (1999).
  Article CAS PubMed Google Scholar
• Grigorieva, I., Thomas, X. & Epstein, J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp. Hematol. 26, 597–603 (1998).
  CAS PubMed Google Scholar
• Vacca, A. et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064–3073 (1999).
  Article CAS PubMed Google Scholar
• Oikawa, T. et al. The proteasome is involved in angiogenesis. Biochem. Biophys. Res. Commun. 246, 243–248 (1998).
  Article CAS PubMed Google Scholar
• Mezquita, J., Mezquita, B., Pau, M. & Mezquita, C. Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J. Cell Biochem. 89, 1138–1147 (2003).
  Article CAS PubMed Google Scholar
• Bladé, J. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 102, 1115–1123 (1998).
  Article PubMed Google Scholar
• Berenson, J. R. et al. Experience with long–term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc. Am. Soc. Clin. Oncol. 22, 710 (2003).
  Google Scholar
• Orlowski, R. Z. et al. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood 102, 449a (2003).
  Article CAS Google Scholar
• Yang, H. H. et al. A phase I/II trial of VELCADE™ and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myeloma (MM). Blood 102, 235a (2004).
  Google Scholar
• Richardson, P. G. et al. Peripheral neuropathy following bortezomib (VELCADE™, formerly PS–341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. Blood 102, 149a (2003).
  Google Scholar